Progression of Severity in Coronavirus Disease 2019 Patients Before Treatment and a Self-Assessment Scale to Predict Disease Severity

Ye Yao

Fudan University School of Public Health

Jie Tian

Fudan University School of Public Health

Xia Meng

Fudan University School of Public Health

Haidong Kan

Fudan University School of Public Health

Lian Zhou

Jiangsu Provincial Center for Disease Control and Prevention

Weibing Wang (✉ wwb@fudan.edu.cn)

Fudan University School of Public Health

Research

Keywords: Coronavirus Disease 2019, Self-Assessment Scale, Severity

Posted Date: October 26th, 2020

DOI: <https://doi.org/10.21203/rs.3.rs-96164/v1>

License: © ⓘ This work is licensed under a Creative Commons Attribution 4.0 International License.

[Read Full License](#)

Abstract

Background: With the pandemic of Coronavirus Disease 2019, differing case-fatality rates and limited resources have led to adoption of separate management strategies for severe and nonsevere disease. For patients in quarantine in the community, self-assessment of COVID-19 severity risk can guide appropriate medical consultation.

Methods: Data from 45,450 patients infected with COVID-19 from January 1 to February 27, 2020 were extracted from the municipal Notifiable Disease Report System in Wuhan, China. T-test and chi-square test were used to investigate the associations of various patient characteristics with disease severity, and multivariable logistic regression models identified strongly correlated variables for inclusion in the scale. Scale accuracy was assessed using receiver operating characteristic analysis. A least absolute shrinkage and selection operator regression cross-validated prediction accuracy.

Results: Twelve scale items - age, gender, illness duration, dyspnea, shortness of breath (clinical evidence of altered breathing), hypertension, pulmonary disease, diabetes, cardio/cerebrovascular disease, number of comorbidities, neutrophil percentage, and lymphocyte percentage - were identified and showed good predictive ability (area under the curve =0.72). After excluding the community healthcare laboratory parameters, the remaining model (the final self-assessment scale) showed similar area under the curve (=0.71).

Conclusions: Our COVID-19 severity self-assessment scale can be used by patients in the community to predict their risk of developing severe illness and the need for further medical assistance. The tool is also practical for use in preliminary screening in community healthcare settings.

Summary

Our study constructed a COVID-19 severity self-assessment scale that can be used by patients in the community to predict their risk of developing severe illness and the need for further medical assistance.

Introduction

Coronavirus Disease 19 (COVID-19) has formed a worldwide pandemic[1], and its clinical spectrum of disease ranges from mild to critical illness. Most COVID-19 patients present with mild symptoms, such as fever and cough, but a small proportion of patients develop severe pneumonia with progression to life-threatening complications, including acute respiratory distress syndrome, multi-organ failure, and death[2]. Consequently, the case-fatality rate differs widely between patients with severe and nonsevere disease. According to the most comprehensive report from the Chinese Centre for Disease Control and Prevention, which reviewed 72,314 cases, the average COVID-19 case-fatality rate is 2.3%, but it is as high as 49% in patients with critical illness[3].

In some countries, such as the United States[4], the Republic of Korea[5], and Scotland, differing case-fatality rates and limited resources have led to the adoption of separate management strategies for severe and nonsevere disease. Particularly in regions with high case volume, the need to conserve the number of available intensive care unit beds and ventilators has dictated home quarantine for patients with nonsevere disease, with reserving hospitalization for patients with severe disease[6–8]; however, the patient who suddenly deteriorates while inappropriately quarantined at home will suffer delay in treatment and in turn, worsened prognosis. For patients in quarantine in community, accurate COVID-19 severity self-assessment can guide appropriate and timely medical consultation. During this pandemic, biological and clinical predictors of COVID-19 infection severity will also assist in the judicious allocation of limited resources.

Previous research has shown that clinical characteristics, including chronic disease, lymphopenia, and elevated D-dimer level, are associated with the severity of COVID-19[9–15], but most of these studies used univariate analysis with comparatively complicated laboratory parameters. A study among hospitalized adults identified through the U.S. COVID-19-Associated Hospitalization Surveillance Network (COVID-NET) showed that increasing age, male sex, and underlying conditions were associated with higher risk of ICU admission and death[16], but it failed to include mild patients who were not hospitalized. Wynants et al.[17] and Urwin et al.[18] presented information available at that time on prediction models on prognosis of COVID-19, but those models were limited in small sample size and rated at high risk of bias resulted in probably optimistic. Further evidence needs to emerge around the validity of these scores. This study aims to further investigate the association of COVID-19 disease severity with numerous patient characteristics, and to develop a convenient severity prediction scale for use in self-assessment at home or in preliminary screening in community healthcare settings.

Methods

Data Sources and Processing

COVID-19 patient data for the period January 1 to February 27, 2020 were extracted from the municipal Notifiable Disease Report System, in Wuhan, Hubei Province. The data was obtained by investigations conducted by epidemiology professionals after the patient was diagnosed. The inclusion criterion was a confirmed COVID-19 diagnosis by positive high-throughput sequencing or reverse-transcription polymerase chain reaction assay of nasal and pharyngeal swab specimens.

Outcome Measurement

The Chinese Diagnosis and Treatment Protocol for COVID-19[19] defines four levels of COVID-19 disease: mild, ordinary, severe, and critical illness; additionally, asymptomatic infection is recognized. We categorized COVID-19 disease severity, based on these definitions, as “nonsevere” (which grouped asymptomatic, mild, and ordinary disease) versus “severe” (grouping severe and critical illness).

Potential Predictive Variables

The study variables included demographic factors (age, gender); present/past medical history (illness duration, quarantine status, and presence of hypertension, pulmonary disease, diabetes mellitus, cardio/cerebrovascular disease, chronic liver disease, and chronic kidney disease); clinical symptoms; blood test parameters (white blood cell count, lymphocyte count and percentage, and neutrophil percentage); and imaging findings (abnormal chest computed tomography scan).

Statistical Analysis

In all, 36 variables were considered as potential predictors of COVID-19 disease severity. T-test and chi-square test were used to compare the differences of each variable in patients with severe and nonsevere disease. The variables that showed significant association with disease severity were then included into logistic regression models for multivariable analysis, to confirm their candidacy for inclusion in the new prediction scale (COVID-19 Severity Self-Assessment Scale). In the logistic modelling, we used the following formulae to calculate the probability and 95% confidence intervals (CIs)[20].

- probability = $\frac{\exp(\Sigma\beta \times X)}{1 + \exp(\Sigma\beta \times X)}$
- lower limit of 95%CI = $\frac{\exp[\Sigma X_n \times \beta_n - \Sigma z \times SE(\beta)]}{1 + \exp[\Sigma X_n \times \beta_n - \Sigma z \times SE(\beta)]}$
- upper limit of 95%CI = $\frac{\exp[\Sigma X_n \times \beta_n + \Sigma z \times SE(\beta)]}{1 + \exp[\Sigma X_n \times \beta_n + \Sigma z \times SE(\beta)]}$

Receiver-operator characteristic (ROC) analysis was performed and the area under the curve (AUC) calculated to verify the accuracy of the final prediction scale. We extracted p-values for AUC by conducting permutation analyses. To avoid the influence of potential collinearity among the variables, least absolute shrinkage and selection operator (LASSO) regression analysis was also performed.

The statistical analysis was performed using MATLAB software, version 2019b (MathWorks Inc). In this study, a p-value less than 0.01 is statistically significant.

Results

Demographic Characteristics

Data were collected from 45,450 patients. The study population had a mean (standard deviation [SD]) age of 53.44 (16.38) years, and 21,689 (47.7%) patients were men. The mean (SD) illness duration was 10.40 (7.90) days (see Figure E1 in the supplementary online data for the distribution). Among all the patients, 7,798 (17.2%) were considered to have severe disease and 37,652 (82.8%) to have nonsevere disease. Accordingly, 37,654 (82.9%) patients were quarantined at home.

Figure 1 shows the distribution of disease severity by age and gender. Both age ($r > 0.91$, $p < 0.0001$) and illness duration ($r > 0.69$, $p < 0.0001$) correlated positively with disease severity, as seen in Fig. 2, and this was unaffected by gender (men and women held similar trend with age and illness duration as showed in Figure E2). Patients with severe disease had a mean (SD) age of 60.85 (15.28) years and illness duration

of 12.55 (7.93) days after symptom onset, compared with patients with nonsevere disease, who had a mean (SD) age of 51.90 (16.17) years and illness duration of 9.95 (7.82) days ($t = 44.85$, $p < 0.0001$ for age; $t = 26.62$, $p < 0.0001$ for illness duration). Quarantine rate did not differ significantly according to illness severity ($\chi^2 = 0.17$, $p = 0.682$) (Table 1).

Table 1
Demographic Characteristics of the Sample

	Severe, mean (sd) / n (%) (n = 7798)	Nonsevere, mean (sd) / n (%) (n = 37652)	t / χ^2	Pvalue
Age (years)	60.85 (15.28)	51.90 (16.17)	$t = 44.85$	$< 0.0001^{**}$
Gender (male)	3908 (50.1%)	17781 (47.2%)	$\chi^2 = 21.64$	$< 0.0001^{**}$
Illness Duration (days)	12.55 (7.93)	9.95 (7.82)	$t = 26.62$	$< 0.0001^{**}$
Quarantine (yes)	6448 (82.7%)	31206 (82.9%)	$\chi^2 = 0.17$	0.682
Abbreviation: sd, standard deviation ** : $p < 0.0001$.				

Clinical Symptoms and Comorbidities

Clinical manifestations were recorded for 4,984 patients and yielded 20 clinical symptoms (Table 2); among these, the incidence of dyspnea ($\chi^2 = 24.56$, $p < 0.0001$) and shortness of breath (defined as clinical evidence of altered breathing) ($\chi^2 = 62.67$, $p < 0.0001$) differed significantly between severe and nonsevere patients. Among 1,326 patients with severe disease, 225 (17.0%) had dyspnea and 296 (22.3%) had shortness of breath; conversely, among the 3,658 patients with nonsevere disease, 425 (11.6%) had dyspnea and 480 (13.1%) had shortness of breath.

Comorbid conditions were recorded for 5,062 patients and were found in a higher proportion of patients with severe versus nonsevere disease (Table 3). Additionally, the number of comorbidities showed significant association with the severity of COVID-19 ($t = 7.96$, $p < 0.0001$). Patients with hypertension, pulmonary disease, diabetes mellitus, and cardio/cerebrovascular disease were more likely to develop severe disease ($t > 15.14$, $p < 0.0001$). Notably, there was no significant difference in the prevalence of chronic liver ($\chi^2 = 0.38$, $p = 0.538$) or kidney disease ($\chi^2 = 2.00$, $p = 0.157$) between patients with severe and nonsevere disease.

Table 2
Reported Symptoms of the Participants

Symptoms	Severe, n (%) (n = 1326)	Nonsevere, n (%) (n = 3658)	χ^2	P value
Fever	1110 (83.7)	2951 (80.7)	5.95	0.015
Vomiting	72 (5.4)	160 (4.4)	2.44	0.118
Dyspnea	225 (17.0)	425 (11.6)	24.56	< 0.0001**
Shortness of Breath [†]	296 (22.3)	480 (13.1)	62.67	< 0.0001**
Expectoration	289 (21.8)	715 (19.5)	3.06	0.080
Sore Throat	55 (4.1)	229 (6.3)	8.08	0.004*
Headache	129 (9.7)	463 (12.7)	7.97	0.005*
Chills	126 (9.5)	372 (10.2)	0.48	0.488
Dry Cough	580 (43.7)	1661 (45.4)	1.09	0.296
Nausea	36 (2.7)	100 (2.7)	0.00	0.971
Runny Nose	19 (1.4)	101 (2.8)	7.31	0.007*
Conjunctival Hyperemia	3 (0.2)	7 (0.2)	0.06	0.808
Muscle Soreness	237 (17.9)	658 (18.0)	0.01	0.926
Chest Pain	22 (1.7)	99 (2.7)	4.51	0.034
Chest Tightness	229 (17.3)	551 (15.1)	3.59	0.058
Diarrhea	127 (9.6)	362 (9.9)	0.11	0.738
Abdominal Pain	3 (0.2)	14 (0.4)	0.70	0.402
Nasal Congestion	23 (1.7)	74 (2.0)	0.42	0.515
Fatigue	537 (40.5)	1335 (36.5)	6.65	0.010*
Joint Soreness	60 (4.5)	224 (6.1)	4.63	0.031
[†] clinical evidence of altered breathing				
*: p < 0.01; **: p < 0.0001.				

Table 3
Reported Comorbidities of the Participants

Comorbidities	Severe, n (%) / mean (sd) (n = 1339)	Nonsevere, n (%) / mean(sd) (n = 3723)	t / χ^2	P value
Hypertension	306 (22.9%)	599 (16.1%)	$\chi^2 = 30.69$	< 0.0001**
Pulmonary Disease	51 (3.8%)	71 (1.9%)	$\chi^2 = 15.14$	< 0.0001**
Diabetes Mellitus	147 (11.0%)	239 (6.4%)	$\chi^2 = 29.06$	< 0.0001**
Cardio-cerebrovascular Disease	126 (9.4%)	214 (5.7%)	$\chi^2 = 21.08$	< 0.0001**
Chronic Liver Disease	14 (1.0%)	32 (0.9%)	$\chi^2 = 0.38$	0.538
Chronic Kidney Disease	17 (1.3%)	31 (0.8%)	$\chi^2 = 2.00$	0.157
No. of Comorbidities [†]	0.50 (0.80)	0.32 (0.66)	t = 7.96	< 0.0001**
[†] total number of comorbid conditions, including hypertension, pulmonary disease, diabetes mellitus, cardio/cerebrovascular disease, chronic liver disease, and chronic kidney disease, for each subject				
**: p < 0.0001.				

Laboratory and Imaging Results

Laboratory results were recorded for 2,471 patients. The percentages of neutrophils and lymphocytes were significantly different in patients with severe versus nonsevere disease: in patients with severe disease, neutrophils were higher (t = - 7.53, p < 0.0001) and lymphocytes were lower (t = 4.67, p < 0.0001; Table 4).

A total of 3,438 patients underwent computed tomography examination, revealing abnormalities in 90.5% of patients with severe disease and 92.2% of patients with nonsevere disease—a nonsignificant difference ($\chi^2 = 2.16$, p = 0.142).

Table 4
Reported Laboratory Results of the Participants

Indexes	Severe, mean(sd) (n = 605)	Nonsevere, mean(sd) (n = 1866)	t	Pvalue
WBC (White Blood Cell Count)	5.69 (3.07)	5.37 (2.87)	2.38	0.018
Lx (Lymphocyte Count)	1.33 (3.47)	1.96 (6.19)	-2.39	0.017
L (Lymphocyte Percentage, %)	20.21 (12.74)	24.90 (13.50)	-7.53	< 0.0001**
N (Neutrophil Percentage, %)	67.17 (21.24)	62.90 (18.94)	4.67	< 0.0001**
**: p < 0.0001.				

Predictor Selection

Among the 36 variables analyzed, 12 showed statistical differences between the groups of patients with severe and nonsevere disease, indicating their potential predictive value: gender, age, illness duration, dyspnea, shortness of breath, hypertension, pulmonary disease, diabetes, cardio/cerebrovascular disease, number of comorbidities, neutrophil percentage, and lymphocyte percentage. Of these, four were strong predictors of severe disease (Table 5): age (odds ratio [OR] = 1.03; 95%CI: 1.02–1.04; p < 0.0001), illness duration (OR = 1.08; 95%CI: 1.06–1.10; p < 0.0001), shortness of breath (OR = 1.64; 95%CI: 1.26–2.13; p = 0.0002), and lymphocyte percentage (OR = 0.98; 95%CI: 0.97–0.99; p < 0.0001).

Table 5
Logistic Regression Model for the Prediction of Severe Disease

Variables	Odds Ratio	95% CI	t	P value
Age	1.03	1.02,1.04	7.28,	< 0.0001**
Gender	1.30	1.06,1.58	2.55	0.011
Illness Duration	1.08	1.06,1.10	9.12	< 0.0001**
Dyspnea	1.18	0.87,1.61	1.07	0.287
Shortness of Breath [†]	1.64	1.26,2.13	3.69	0.0002*
Hypertension	0.86	0.45,1.67	-0.43	0.664
Pulmonary Disease	1.67	0.73,3.81	1.23	0.220
Diabetes Mellitus	1.29	0.64,2.58	0.71	0.480
Cardio-cerebrovascular Disease	0.86	0.42,1.77	-0.41	0.684
No. of Comorbidities	1.03	0.57,1.85	0.10	0.921
L (Lymphocyte Percentage)	0.98	0.97,0.99	-4.79	< 0.0001**
N (Neutrophil Percentage)	1.00	0.99,1.00	-1.17	0.242
[†] clinical evidence of altered breathing				
*: p < 0.01; **: p < 0.0001.				

Effect size of strong predictors at different disease stages

To further understand whether the above strong predictors have the same effect in different disease stages, we analyzed effect size of three strong severity predictors (age, shortness of breath, and lymphocyte percentage) at different illness duration. As sample size differed at different stages, we applied Cohen's *d* for continuous variables and odds ratio for categorical variables as effect size to describe statistical results. As shown in Fig. 3, all the three variables were always helpful predictors to find out severe patients with illness duration increasing. The risk factors won't change at different disease stages.

Construction and Performance of the COVID-19 Severity Self-Assessment Scale

As described, regression modelling identified 12 variables for inclusion in the prediction scale; however, blood tests cannot be performed by patients doing self-assessment, and the two blood test indicators

(neutrophil percentage and lymphocyte percentage) were excluded from the final scale, leaving a 10-item scale.

Figure 4 shows the results of the ROC analysis evaluating the accuracy of different model scales. The AUC of the full logistic regression model, with all 12 variables showing strong association to disease severity, was 0.72 ($p < 0.0001$). Following removal of neutrophil percentage and lymphocyte percentage, the remaining model (the final “COVID-19 Severity Self-Assessment Scale”) showed a similar AUC = 0.71 ($p < 0.0001$) and further, higher accuracy in older-aged (≥ 65 years) patients (AUC = 0.75, $p < 0.0001$). The LASSO regression extracted similar results, indicating no confounding collinearity between the variables and cross-validating the prediction accuracy.

The final 10-item scale yielded a total score of 100 points, with higher score indicating a higher risk for severe illness. ROC analysis determined the cutoff value of 49.65, with scores above 49.65 predicting high risk. With this score, the final scale can correctly identify 87% patients.

Once the predictive variables were determined and the self-assessment scale developed, an online calculator tool was constructed to allow patients access to expedient results (<http://180.167.250.222:10080/COVID-19-Severity-Self-Assessment-Scale.html>; Fig. 5).

Discussion

The study results showed that age, illness duration after onset, shortness of breath, and lymphocyte percentage are key factors in predicting whether COVID-19 infection will advance to severe disease. Notably, quarantine does not change the likelihood of developing a more serious illness. Fever is often thought to be associated with disease severity, such as in influenza, but we found no significant difference in fever rates between patients with severe and nonsevere COVID-19 disease. Previous studies(9, 11) have found comorbid chronic diseases to be correlated with increased disease severity among COVID-19 patients. A study outside Wuhan by Shi et al. also found that hypertension is a risk factor for severe COVID-19(21). Similarly, we found that four chronic diseases were more prevalent in patients with severe disease. While comorbidities showed weaker significance in the multivariate analysis, they were nevertheless included in the scale for higher accuracy of the model. Surprisingly, abnormality on chest computed tomography or X-ray exam did not distinguish patients with severe illness from those with nonsevere illness; however, our data only included the presence or absence of abnormality, and more detailed analysis of the abnormalities, e.g., of lesion size and distribution, might have disclosed different levels of severity—further analysis of the results by specialists is warranted(22, 23).

Previously, older age has been reported as an important risk factor in SARS and MERS(24, 25). Our study confirmed that increased age was associated with COVID-19 severity and the severity risk would increase 1.32 times with every 10 years old. Older age has also been mentioned a strong relationship with death in patients with COVID-19(10). Apart from age, we also found that illness duration after onset held a significant association with COVID-19 severity. The risk would increase 2.22 times with every 10 days

after illness onset. Thus, we strongly recommend early detection and treatment in healthcare settings for patients with COVID-19, especially aged patients, to reduce the mortality rate. Shortness of breath, a symptom written in the Chinese Protocol on Prevention and Control of COVID-19(19), was confirmed as a risk factor of COVID-19 severity in our study. Patients with shortness of breath held 1.64 times higher severity risk. Lymphocyte percentage, as a common blood test parameter, could be easily extracted in the community healthcare. There are several previous studies which mentioned that lymphocyte was a risk factor of COVID-19 severity(12, 26) with comparatively small sample sizes. In this study, we cross-validated this association with a large sample size and quantified that the severity risk would increase 1.26 times with 10% lymphocyte decreasing.

We developed a self-assessment tool to predict the development of severe illness among COVID-19 infected patients in quarantine at home. To our knowledge, a list of risk scores has been established for COVID-19 mortality and severity. For example, a mortality risk prediction score was currently available online and methodologically suitable for use in the community(27). However, it was not developed with COVID-19 patients' data, and therefore further validation should be required. There are some studies that have developed similar critical illness risk score(28, 29), but they rarely pay attention to the effect of the illness duration on the severity of the disease. The possible reason is that the confirmed was immediately sent to a medical institution as soon as it was discovered, in the case of sufficient medical resources, such as in the late stage of the outbreak in China. We analyzed the data of the patients in the early stage of the outbreak in Wuhan and found that the longer they have been ill, the greater the possibility that the disease will develop into severe. Existing COVID-19 severity prediction models(29–33) showed that complex laboratory indicators, such as direct bilirubin and lactate dehydrogenase, could help us to evaluate disease progression more accurately. On the other hand, results from these indicators relied a lot on the availability of specialized laboratory parameters. Furthermore, hospital visits would increase COVID-19 cross-infection risks. The COVID-19 Severity Self-Assessment Scale we constructed needn't complex laboratory parameters and offers relatively high accuracy, which makes it convenient and practical for use in home self-assessment and for preliminary rapid screening in community healthcare settings.

To the best of our knowledge, this study included the most patients with COVID-19 before treatments in the early stage of the Wuhan outbreak. The lack of medical resources caused by the sudden outbreak prevented patients from receiving timely treatment, which resulted in a longer disease course (Figure E1 in the supplementary online data) that more closely resembled the natural progression of the disease. Despite these strengths, the data used in the scale construction were entirely from China, which could potentially limit the generalizability of the findings and use of the scale in other countries.

Conclusions

Twelve scale items - age, gender, illness duration, dyspnea, shortness of breath (clinical evidence of altered breathing), hypertension, pulmonary disease, diabetes, cardio/cerebrovascular disease, number of comorbidities, neutrophil percentage, and lymphocyte percentage - were identified and showed good

predictive ability of whether confirmed patients would develop severe disease. After excluding the laboratory parameters, we constructed a COVID-19 severity self-assessment scale that can be used by patients in the community to predict their risk of developing severe illness and the need for further medical assistance. The tool is also practical for use in preliminary screening in community healthcare settings.

Declarations

Ethics approval and consent to participate

The study was conducted according to the principles of the Declaration of Helsinki, and all data were de-identified to protect patient confidentiality. Ethical approval for this study was obtained from the School of Public Health, Fudan University.

Consent for publication

Not applicable

Availability of data and materials

The datasets used and analysed during the current study are available from the corresponding author on reasonable request.

Competing interests

The authors declare that they have no competing interests.

Funding

This work was supported by the Bill & Melinda Gates Foundation [grant number INV-006277]; and the Shanghai Sailing Program [grant number 17YF142600].

Authors' contributions

YY and JT contributed equally. HDK, LZ and WBW contributed equally to the correspondence work. YY and WBW designed the study. YY, XM, HDK, LZ, and WDW collected, analyzed and interpreted the data. YY and XM performed the statistical analysis of the data. YY and JT drafted the manuscript. All authors critically reviewed and approved the final version of the manuscript.

Acknowledgments

We thank Eleanor Scharf, MSc(A), from Liwen Bianji, Edanz Editing China (www.liwenbianji.cn/ac), for editing the English text of a draft of this manuscript.

References

1. WHO Coronavirus Disease (COVID-19) Dashborad [<https://covid19.who.int/>]
2. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, Zhang L, Fan G, Xu J, Gu X, et al: **Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China.** *Lancet* 2020, **395**:497-506.
3. Wu Z, McGoogan JM: **Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention.** *Jama* 2020.
4. **Quarantine and Isolation** [<https://www.cdc.gov/coronavirus/2019-ncov/if-you-are-sick/quarantine-isolation.html>]
5. Oh J, Lee JK, Schwarz D, Ratcliffe HL, Markuns JF, Hirschhorn LR: **National Response to COVID-19 in the Republic of Korea and Lessons Learned for Other Countries.** *Health Syst Reform* 2020, **6**:e1753464.
6. Swiss Academy Of Medical S: **COVID-19 pandemic: triage for intensive-care treatment under resource scarcity.** *Swiss Med Wkly* 2020, **150**:w20229.
7. Joebges S, Biller-Andorno N: **Ethics guidelines on COVID-19 triage-an emerging international consensus.** *Crit Care* 2020, **24**:201.
8. Phua J, Weng L, Ling L, Egi M, Lim CM, Divatia JV, Shrestha BR, Arabi YM, Ng J, Gomersall CD, et al: **Intensive care management of coronavirus disease 2019 (COVID-19): challenges and recommendations.** *Lancet Respir Med* 2020, **8**:506-517.
9. Guan WJ, Liang WH, Zhao Y, Liang HR, Chen ZS, Li YM, Liu XQ, Chen RC, Tang CL, Wang T, et al: **Comorbidity and its impact on 1590 patients with COVID-19 in China: a nationwide analysis.** *Eur Respir J* 2020, **55**.
10. Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, Xiang J, Wang Y, Song B, Gu X, et al: **Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study.** *Lancet* 2020, **395**:1054-1062.
11. Li B, Yang J, Zhao F, Zhi L, Wang X, Liu L, Bi Z, Zhao Y: **Prevalence and impact of cardiovascular metabolic diseases on COVID-19 in China.** *Clin Res Cardiol* 2020, **109**:531-538.
12. Tan L, Wang Q, Zhang D, Ding J, Huang Q, Tang YQ, Wang Q, Miao H: **Lymphopenia predicts disease severity of COVID-19: a descriptive and predictive study.** *Signal Transduct Target Ther* 2020, **5**:33.
13. Zhang JJ, Dong X, Cao YY, Yuan YD, Yang YB, Yan YQ, Akdis CA, Gao YD: **Clinical characteristics of 140 patients infected with SARS-CoV-2 in Wuhan, China.** *Allergy* 2020.
14. Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX, Liu L, Shan H, Lei CL, Hui DSC, et al: **Clinical Characteristics of Coronavirus Disease 2019 in China.** *N Engl J Med* 2020, **382**:1708-1720.
15. Wu S, Du Z, Shen S, Zhang B, Yang H, Li X, Cui W, Chen F, Huang J: **Identification and validation of a novel clinical signature to predict the prognosis in confirmed COVID-19 patients.** *Clinical Infectious Diseases* 2020.

16. Kim L, Garg S, O'Halloran A, Whitaker M, Pham H, Anderson EJ, Armistead I, Bennett NM, Billing L, Como-Sabetti K, et al: **Risk Factors for Intensive Care Unit Admission and In-hospital Mortality among Hospitalized Adults Identified through the U.S. Coronavirus Disease 2019 (COVID-19)-Associated Hospitalization Surveillance Network (COVID-NET).** *Clinical Infectious Diseases* 2020.
17. Wynants L, Van Calster B, Collins GS, Riley RD, Heinze G, Schuit E, Bonten MMJ, Damen JAA, Debray TPA, De Vos M, et al: **Prediction models for diagnosis and prognosis of covid-19 infection: systematic review and critical appraisal.** *Bmj* 2020, **369**:m1328.
18. **What prognostic clinical risk prediction scores for COVID-19 are currently available for use in the community setting?** [<https://www.cebm.net/covid-19/what-prognostic-clinical-risk-prediction-scores-for-covid-19-are-currently-available-for-use-in-the-community-setting/>]
19. **Notification on the issuance of COVID-19 protocols**
[<http://www.nhc.gov.cn/xcs/zhengcwj/202003/46c9294a7dfe4cef80dc7f5912eb1989.shtml>]
20. Xu J, Long JS: **Confidence Intervals for Predicted Outcomes in Regression Models for Categorical Outcomes.** *Stata Journal* 2005, **5**:537-559.
21. Shi Y, Yu X, Zhao H, Wang H, Zhao R, Sheng J: **Host susceptibility to severe COVID-19 and establishment of a host risk score: findings of 487 cases outside Wuhan.**
22. Yuan M, Yin W, Tao Z, Tan W, Hu Y: **Association of radiologic findings with mortality of patients infected with 2019 novel coronavirus in Wuhan, China.** *PLoS One* 2020, **15**:e0230548.
23. Li B, Li X, Wang Y, Han Y, Wang Y, Wang C, Zhang G, Jin J, Jia H, Fan F, et al: **Diagnostic value and key features of computed tomography in Coronavirus Disease 2019.** *Emerg Microbes Infect* 2020, **9**:787-793.
24. Choi KW, Chau TN, Tsang O, Tso E, Chiu MC, Tong WL, Lee PO, Ng TK, Ng WF, Lee KC, et al: **Outcomes and prognostic factors in 267 patients with severe acute respiratory syndrome in Hong Kong.** *Ann Intern Med* 2003, **139**:715-723.
25. Hong KH, Choi JP, Hong SH, Lee J, Kwon JS, Kim SM, Park SY, Rhee JY, Kim BN, Choi HJ, et al: **Predictors of mortality in Middle East respiratory syndrome (MERS).** *Thorax* 2018, **73**:286-289.
26. Liu D, Wang Y, Lan L, Liu Y, Zhao B, Bao L, Chen H, Yang M, Li Q, Zeng Y: **Overall reduced lymphocyte subsets worsening disease severity and prognosis in COVID-19 severe cases with diabetes mellitus in Chengdu, China, 08 April 2020, PREPRINT (Version 1) 2020.**
27. **Coronavirus Risk Calculator** [<https://www.coronavirusrisk.org/risk-calculator/>]
28. Liang W, Liang H, Ou L, Chen B, Chen A, Li C, Li Y, Guan W, Sang L, Lu J, et al: **Development and Validation of a Clinical Risk Score to Predict the Occurrence of Critical Illness in Hospitalized Patients With COVID-19.** *JAMA Intern Med* 2020.
29. Bai X, Fang C, Zhou Y, Bai S, Liu Z, Chen Q, Xu Y, Xia T, Gong S, Xie X, et al: **Predicting COVID-19 malignant progression with AI techniques.** *medRxiv* 2020:2020.2003.2020.20037325.
30. Gong J, Ou J, Qiu X, Jie Y, Chen Y, Yuan L, Cao J, Tan M, Xu W, Zheng F, et al: **A Tool to Early Predict Severe Corona Virus Disease 2019 (COVID-19) : A Multicenter Study using the Risk Nomogram in Wuhan and Guangdong, China.** *Clin Infect Dis* 2020.

31. Huang H, Cai S, Li Y, Li Y, Fan Y, Li L, Lei C, Tang X, Hu F, Li F, Deng X: **Prognostic factors for COVID-19 pneumonia progression to severe symptom based on the earlier clinical features: a retrospective analysis.** *medRxiv* 2020:2020.2003.2028.20045989.

32. Zhou Y, Yang Z, Guo Y, Geng S, Gao S, Ye S, Hu Y, Wang Y: **A New Predictor of Disease Severity in Patients with COVID-19 in Wuhan, China.** *medRxiv* 2020:2020.2003.2024.20042119.

Figures

Figure 1

Distribution of Disease Severity by Age and Gender. Severity Ratio refers to the proportion of patients with severe disease. Age correlated positively with Coronavirus Disease 2019 severity ($r>0.91$, $p<0.0001$), and this was unaffected by gender. Severity Ratio refers to the proportion of patients with severe disease.

Figure 2

Distribution of Illness Severity by Age and Illness Duration. Severity Ratio refers to the proportion of patients with severe disease. This increased with advancing age and illness duration.

Figure 3

Effect size of strong predictors at different disease stages The effect size (Cohen's d for continuous variables and odds ratio for categorical variables) of three strong severity predictors (age, shortness of breath, and lymphocyte percentage) with different illness durations. All the three variables could help to find out severe patients at different disease stages.

Figure 4

ROC Curves for Patients with Severe Disease. A ROC curve was generated for all 12 variables (i.e., 10 self-assessment variables and 2 blood test parameters) that showed strong correlation with disease severity (blue line, AUC=0.72, $p<0.0001$). Then, separate ROC curves were generated for the 10 variables in the final self-assessment scale (green line, AUC=0.71, $p<0.0001$) and for the same 10 variables, in the older-aged (not less than 65 years old) patients (red line, AUC=0.75, $p<0.0001$). Abbreviations: ROC, receiver operating characteristic; AUC, area under the (ROC) curve.

新冠重症自查量表 COVID-19 Severity Self-Assessment Scale

请回答以下问题进行评分。 / Please answer the questions below to calculate.

1. 年龄 / Age (岁 / years)	<input type="text"/>	6. 高血压病史 / Hypertension History	☐ 是 / yes ☐ 否 / no
2. 性别 / Gender	☐ 男 / Male ☐ 女 / Female	7. 肺部疾病病史 / Pulmonary Disease History	☐ 是 / yes ☐ 否 / no
3. 病程 (发病后几天) / Illness Duration after Symptom Onset (天 / Days)	<input type="text"/>	8. 糖尿病病史 / Diabetes Mellitus History	☐ 是 / yes ☐ 否 / no
4. 呼吸困难 / Dyspnea	<input type="text" value="0"/>	9. 心脑血管疾病病史 / Cardio-cerebrovascular Disease History	☐ 是 / yes ☐ 否 / no
5. 气促 / Shortness of Breath (clinical evidence of altered breathing)	<input type="text" value="0"/>	10. 共病数量 / No. of Comorbidities	<input type="text" value="0"/>
		总分 / Total point:	<input type="text"/>
		危险分层 / Risk group:	<input type="text"/>

计算 / Calculate

备注 Notes:

呼吸困难症状评分, 0: 无症状; 1: 平地快步行走或步行爬小坡时出现气短; 2: 由于气短, 平地行走时比同龄人慢或者需要停下来休息; 3: 在平地行走100米左右或数分钟后需要停下来喘气; 4: 因严重呼吸困难以至于不能离开家, 或在穿衣服、脱衣服时出现呼吸困难。

Dyspnea Scale, 0: No symptoms; 1: Dyspnea when hurrying or walking up a slight hill; 2: Walks slower than people of the same age because of dyspnea or has to stop for breath when walking at own pace; 3: Stops for breath after walking 100 yards (91 m) or after a few minutes; 4: Too dyspneic to leave house or breathless when dressing.

气促症状评分, 0: 无症状; 1: 轻度; 2: 中度; 3: 重度; 4: 严重。

Shortness of Breath Scale (clinical evidence of altered breathing), 0: No symptoms; 1: Mild; 2: Moderate; 3: Strong; 4: Severe.

共病病史包括高血压、肺部疾病、糖尿病、心脑血管疾病、慢性肝病、慢性肾病与免疫缺陷类疾病。

Comorbidity includes hypertension, pulmonary disease, diabetes mellitus, cardio-cerebrovascular disease, chronic liver disease and chronic kidney disease.

Figure 5

The Online Coronavirus Disease 2019 Severity Self-Assessment Scale. The scale is available at: <http://180.167.250.222:10080/COVID-19-Severity-Self-Assessment-Scale.html> Abbreviation: COVID-19, Coronavirus Disease 2019 Note: Shortness of breath is defined here as clinical evidence of altered breathing.

Supplementary Files

This is a list of supplementary files associated with this preprint. Click to download.

- [Additionalfile.docx](#)